JUST IN: FDA grants fast-track approval to experimental Alzheimer's drug
Data for another promising Alzheimer's treatment by Eli Lilly that is similar to lecanemab is expected midyear., which limits coverage of the class of drugs lecanemab is part of to patients enrolled in clinical trials or CMS-approved comparative studies.
“This is encouraging news, but the approval of lecanemab is just the first step,” said Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation. The report authors said that the patient experienced brain bleeds that are "unusual" when receiving stroke treatment on its own, but could not pinpoint lecanemab as the primary cause of death., in 2021, despite strong objections from the agency's own advisory panel. Scientists said the drug lacked evidence that it even worked.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA grants accelerated approval to Alzheimer's drug for people with early stage diseaseBREAKING: FDA grants accelerated approval to new Alzheimer's treatment that can slow cognitive decline in people with early stages of the disease.
Read more »
New Alzheimer’s Drug Approved by FDA, Promises to Slow DiseaseBreaking: A new Alzheimer's drug has been cleared for use in the U.S. Doctors say it could transform the way the disease is treated.
Read more »
Alzheimer’s drug that slows cognitive decline gets FDA approvalThe drug, lecanemab, removes a sticky protein from the brain called amyloid beta, which is thought to play a key role in the memory-robbing illness.
Read more »
FDA approves new Alzheimer’s drug that appears to slow progression of diseaseBREAKING: FDA approves Alzheimer’s drug shown in clinical trials to slow cognitive decline in patients in the early stages of the illness.
Read more »
FDA Approves Alzheimer's Drug That Modestly Slows DiseaseThe drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s.
Read more »
FDA approves Leqembi, Alzheimer's drug that modestly slows diseaseALZHEIMER'S DRUG: The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology. MORE:
Read more »